Efficacy and Safety of Inotuzumab Ozogamicin in Treating Adult Patients With Ph Negative ALL With Minimal Residual Disease Positive After Induction Chemotherapy

NCT05456698 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

31

Enrollment

OTHER

Sponsor class

Conditions

Acute Lymphocytic Leukemia

Interventions

DRUG: Inotuzumab ozogamicin

Sponsor

Institute of Hematology & Blood Diseases Hospital, China